( Purpose This app...)Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System

Purpose

This application note describes the use of the new Q TRAP LC/MS/MS system with Metabolite ID software for Phase I and Phase II metabolite identification and discusses its unique capabilities that increase your productivity and confidence in your results.

Overview

Current trends in drug development are placing more emphasis on characterization of potential drug candidates earlier in the discovery process. The goal is to take more qualified drug candidates to preclinical testing and clinical trials. This shift in focus will enable drug researchers to save time and money. Nearly 60% of the costs to develop a new drug are incurred in the clinical trials phase, so there is much to be gained by selecting only the most promising drug candidates for testing at this level. Early discovery ADME (adsorption, distribution, metabolism, and excretion) studies are critical to predict a drug candidates success in further downstream testing.

Early assessment of drug metabolism of in vitro and in vivo samples provides initial information about a potential drugs biotransformation and metabolite characterization. To obtain maximum characterization information, including chemical structure and quantity, LC/MS (liquid chromatography/mass spectrometry) is often employed because it has sufficient sensitivity and specificity to measure nanogram levels of metabolites in complex matrices. Ion trap mass spectrometers are widely used to identify metabolites, and triple quadrupole mass spectrometers are generally used to measure the amount, or concentration of metabolites detected.

Key Features of the Q TRAP System

Exceptional sensitivity for metabolite identification and characterization

Powerful advanced scan modes, including neutral loss and precursor ion scans, can be used in flexible combinations to achieve unpre
'"/>

Source: